Bremelanotide (PT-141) Dosing Protocol

Melanocortin Receptor Activation (MC3R and MC4R)

Dopaminergic Enhancement

One of the most important things bremelanotide does is boost dopamine — the brain chemical most closely tied to motivation, pleasure, and wanting. When MC3R and MC4R are activated, they trigger increased dopamine release in the brain's reward system (the same network involved in enjoying food, music, or anticipation of something exciting). This dopamine boost amplifies your natural arousal signals and can make it easier to feel interested in and responsive to sexual cues.

Serotonin Modulation

There's also evidence that bremelanotide may reduce the "braking" effect that serotonin has on sexual desire. Serotonin is a brain chemical that, among many roles, can suppress sexual interest — which is why some antidepressants (SSRIs) lower libido as a side effect. By dialing down this serotonin brake while simultaneously boosting the dopamine accelerator, bremelanotide works on both sides of the equation: less suppression and more activation. This two-pronged approach is similar in concept to flibanserin (Addyi) but works through a different set of brain signals.

MC1R Activation and Melanogenesis

Bremelanotide also activates MC1R, the receptor responsible for melanin production (the pigment that determines skin and hair color). This is why repeated use — especially more than 8 doses per month — can cause darkening of the skin, gums, or breasts. This side effect is separate from the sexual-desire mechanism and is discussed in detail in the Side Effects section below.

Q1: What is the starting dose of bremelanotide (PT-141)?

The recommended starting dose for first-time users is 0.5 mg administered subcutaneously. This initial test dose allows assessment of individual tolerance, particularly for nausea and blood-pressure response. Some clinicians use a split-dose approach: inject 0.5 mg, wait 30 minutes, and if tolerated, administer an additional 0.5 mg. Users typically titrate to a therapeutic range of 1.5-1.75 mg over 2-3 subsequent administrations. The FDA-approved Vyleesi dose is 1.75 mg.

Q2: What is bremelanotide's half-life?

The elimination half-life of bremelanotide is approximately 2.7 hours, with a range of 1.9 to 4.0 hours per prescribing information. Peak plasma concentration occurs at about 1 hour (range 0.5-1.0 hours) after subcutaneous injection, and SubQ bioavailability is effectively complete. Although the drug clears from your blood quickly, its effects on desire and arousal can persist for up to about 16 hours, and some users report residual libido-enhancing effects for 24-72 hours.

Q3: What results can be expected from bremelanotide?

In RECONNECT phase 3 trials involving 1,267 premenopausal women with HSDD, bremelanotide produced statistically significant increases in sexual desire and significant reductions in distress associated with low desire (both primary endpoints p < 0.0001 vs placebo). In male ED studies, PT-141 produced significant erectogenic effects; in sildenafil non-responders, 34% of treated men reported erections sufficient for intercourse versus 9% on placebo. Combination studies with low-dose sildenafil reported over five-fold increases in erectile duration.

Q4: How do you reconstitute bremelanotide (PT-141)?

Add bacteriostatic water to the lyophilized PT-141 vial using a sterile syringe. For a 10 mg vial, adding 2.0 mL BAC water yields 5 mg/mL concentration, where a 1.75 mg dose equals 0.35 mL (35 units on a U-100 insulin syringe). Direct the water stream against the glass wall, not directly onto powder. Gently swirl or roll to dissolve, never shake. Label with date and concentration, refrigerate at 2-8C, and use within 28-30 days. For custom vial and water-volume calculations, use https://www.peppal.app/calculator.

Q5: Is bremelanotide (PT-141) FDA-approved?

Yes. Bremelanotide was approved by the FDA on June 21, 2019, under the brand name Vyleesi, specifically for acquired, generalized HSDD in premenopausal women, and was designated first-in-class. Use for erectile dysfunction in men, male low libido, or postmenopausal women is off-label.

Q6: What are the most common side effects of bremelanotide?

The most common side effect is nausea, reported in about 40% of trial participants, with roughly 8% discontinuing treatment because of it. Other common effects include flushing (20.3%), injection-site reactions (13.2%), headache (11.3%), and vomiting (4.8%). Bremelanotide also causes transient blood-pressure increases averaging about 6/3 mmHg that resolve within about 12 hours. A unique long-term concern is hyperpigmentation, which may be irreversible in some cases.

Q7: How does bremelanotide compare to Viagra/Cialis (PDE5 inhibitors)?

They work in completely different ways. Viagra and Cialis increase blood flow to the genitals by relaxing blood vessels — they help with the physical mechanics of erections but don't change desire. Bremelanotide works in the brain, activating melanocortin pathways that boost sexual desire and motivation. So bremelanotide is primarily about wanting, while Viagra/Cialis is primarily about physical function. Some people use both for different reasons.

Q8: What vial sizes are available for PT-141?

Research suppliers commonly offer bremelanotide (PT-141) in 5 mg and 10 mg lyophilized vial sizes. The 10 mg format is often more economical across variable dose requirements. The FDA-approved commercial product (Vyleesi) is a prefilled autoinjector containing 1.75 mg per 0.3 mL dose.

Q9: How much bacteriostatic water should be added to a PT-141 vial?

BAC water volume depends on vial size and target concentration. For a 10 mg vial, adding 2.0 mL creates 5 mg/mL (1.75 mg equals 35 units), while 3.0 mL creates about 3.33 mg/mL (1.75 mg is about 53 units). For a 5 mg vial, 1.0 mL creates 5 mg/mL and 2.0 mL creates 2.5 mg/mL. Higher concentrations reduce injection volume, while lower concentrations improve measurement precision. Use https://www.peppal.app/calculator for exact conversion.

Q10: What is the maximum dose of bremelanotide studied?

The common maximum subcutaneous protocol dose is 2.0 mg. Early phase 1 and 2 intranasal studies used doses up to 20 mg, and early SubQ studies explored higher doses in male subjects, but the FDA-approved dose is 1.75 mg based on dose-finding efficacy and tolerability balance. Higher exposure increases side-effect burden, particularly nausea and hyperpigmentation.

Q11: How should reconstituted bremelanotide (PT-141) be stored?

Reconstituted bremelanotide should be refrigerated at 2-8C (36-46F) and used within 28-30 days. Use bacteriostatic water for multi-dose workflows, protect from light, and avoid repeated freeze-thaw cycles. Single-use frozen aliquots at -20C can be used for longer storage windows in some protocols.

Q12: What were the key clinical trials for bremelanotide?

The pivotal trials were the two phase 3 RECONNECT studies (NCT02333071 and NCT02338960) in a combined 1,267 premenopausal women with HSDD, evaluating 1.75 mg subcutaneous bremelanotide over 24 weeks. Both met co-primary endpoints with significant improvements in desire and distress outcomes (p < 0.0001 vs placebo). A 52-week open-label extension reported sustained efficacy and safety. Earlier phase 1 and phase 2 male ED studies by Diamond, Rosen, and Safarinejad established erectogenic effects and informed later protocol interest.

Q13: Where can I calculate reconstitution and syringe units?

Use the PepPal calculator for exact dose-to-unit conversions.

Q14: Where can I compare peptide suppliers?

Browse the PepPal supplier directory for current supplier listings.